936623-90-4

：If you are looking for a supplier or manufacturer of LCZ696 (CAS No.: 936623-90-4) please contact us. We have more than 10 years of experience in custom synthesis of compounds. We can provide customers with custom synthesis from grams to kilograms and the production of tons of compounds. Now, we also hope to meet your needs for LCZ696 (CAS No.: 936623-90-4) and other compounds. We can provide high-quality compounds and good service for you.

Send Inquiry

Product Description

Name	LCZ696
Synonyms	Entresto;L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1'-biphenyl]-4-pentanoate, sodium salt, hydrate (2:2:6:5);trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3-methyl-2-(pentanoyl{2”-(tetrazol-5-ylate)biphenyl-4-ylmethyl}amino)butyrate] hemipentahydrate;trisodium 3-((1S,3R)-1-(biphenyl-4-ylmethyl)-3-(ethoxycarbonyl)butylcarbamoyl)propionate (S)-3-methyl-2-(pentanoyl-(2-(tetrazol-1-at-5-yl)biphenyl-4'-ylmethyl)amino)butyrate hemipentahydrate
Molecular Formula	C₄₉H₅₉N₆Na₃O₈
Molecular Weight	928.99700
CAS Number	936623-90-4
purity	≥97%
Storage conditions	Sealed in dry,2-8°C

Application：Valsartan/sacubitril (brand name Entresto) (CAS No.: 936623-90-4) is a combination drug for use in heart failure developed by Novartis. It consists of the angiotensin receptor blocker valsartan and the neprilysin inhibitor sacubitril, in a 1:1 mixture by molecule count. It may be used instead of an ACE inhibitor or an angiotension receptor blocker in people with heart failure with reduced ejection fraction.
Side effects include angioedema, kidney problems, and low blood pressure. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor" (ARNi).
It was approved under the FDA's priority review process on July 7, 2015. It is also approved in Europe. The wholesale cost for a year of Entresto is $4,560 per person as of 2015. Similar class generic drugs without sacubitril, such as valsartan alone, cost approximately $48 a year.

Hot Tags: